<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1468">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01885000</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.29107</org_study_id>
    <nct_id>NCT01885000</nct_id>
  </id_info>
  <brief_title>Patient-Reported Outcome Of Facial Erythema (PROOF)</brief_title>
  <acronym>PROOF</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Sweden: Medical Products Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the patient-reported outcomes (feedbacks of
      patients)of a new drug for the treatment of erythema of rosacea (central facial redness).
      The feedback of patients receiving the active drug will be compared to the feedback of
      patients receiving the placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>satisfaction with the overall study treatment</measure>
    <time_frame>Day 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in satisfaction with appearance of facial skin</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean CEA</measure>
    <time_frame>3 hour after drug application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subject reporting a treatment-related adverse event</measure>
    <time_frame>Throughout the study</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Rosacea</condition>
  <condition>Erythema</condition>
  <arm_group>
    <arm_group_label>Brimonidine tartrate 0.5% gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once-daily brimonidine tartrate 0.5% gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once-daily brimonidine tartrate vehicle gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>once-daily brimonidine tartrate 0.5% gel</intervention_name>
    <arm_group_label>Brimonidine tartrate 0.5% gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>once-daily brimonidine tartrate vehicle gel</intervention_name>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects age of 18 years or older,

          -  A clinical diagnosis of facial rosacea,

          -  A Patient Self-Assessment score of 4 (severe) at Baseline prior to the study drug
             application,

          -  A Clinician's Erythema Assessment (CEA) score of 3 (moderate) or 4 (severe) at
             Baseline prior to the study drug application,

        Exclusion Criteria:

          -  More than 5 facial inflammatory lesions (papules or pustules) of rosacea,

          -  Any uncontrolled chronic or serious disease or medical condition that may either
             interfere with the interpretation of the clinical trial results, or put the subject
             at significant risk if the subject participates in the clinical trial as judged by
             the investigator,

          -  Known or suspected allergies or sensitivities to any component of the study drugs,
             including the active ingredient brimonidine tartrate (see Investigator's Brochure),

          -  Female who is pregnant or lactating.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Klinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universität</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik für Hautkrankheiten</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Hautklinik Eberhard Karls Universität Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Dermatologie, Allergologie und Dermatochirurgie</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentroDerm Gesellschaft für dermatolgische Forschung mbH (GmbH)</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capio Citykliniken</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Läkarhuset Odenplan</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Tayside</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whipps Cross University Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrogate District Hospital</name>
      <address>
        <city>Yorkshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 24, 2014</lastchanged_date>
  <firstreceived_date>June 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosacea</mesh_term>
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brimonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
